1.
Worldwide access to treatment for end-stage kidney disease: a systematic review
by Liyanage, Thaminda, MBBS
The Lancet (British edition), 2015, Vol.385 (9981), p.1975-1982
2.
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
by Xie, Xinfang, MD
The Lancet (British edition), 2016, Vol.387 (10017), p.435-443
3.
A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension
by Olsen, Michael H, DMSc
The Lancet (British edition), 2016, Vol.388 (10060), p.2665-2712
4.
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
by Matthews, David R
Diabetologia, 2019-06, Vol.62 (6), p.926-938
5.
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
by Jun, Min, MSc
The Lancet (British edition), 2010, Vol.375 (9729), p.1875-1884
6.
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)—A randomized placebo-controlled trial
by Neal, Bruce, PhD
The American heart journal, 2013, Vol.166 (2), p.217-223.e11
7.
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials
by Heerspink, Hiddo J Lambers, PharmD
The Lancet (British edition), 2009, Vol.373 (9668), p.1009-1015
8.
The Affordable Dialysis Prize steams ahead
by Knight, John
The Lancet (British edition), 2016, Vol.387 (10023), p.1040-1040
9.
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON study
by Oshima, Megumi
Diabetologia, 2019-07-13, Vol.62 (11), p.1988-1997
10.
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
by Zhou, Zien
Diabetologia, 2019-10, Vol.62 (10), p.1854-1867
11.
Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy
by Yamout, Hala
American journal of nephrology, 2014-08, Vol.40 (1), p.64-74
12.
Global kidney disease
by Neuen, Brendon L
The Lancet (British edition), 2013, Vol.382 (9900), p.1243-1243
13.
Association between Serum Alkaline Phosphatase and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial
by Badve, Sunil V.
Canadian journal of kidney health and disease, 2015-08-18, Vol.2, p.33-33
14.
Effects of fibrates on cardiovascular outcomes – Authors' reply
by Perkovic, Vlado
The Lancet (British edition), 2010, Vol.376 (9746), p.1051-1052
15.
Blood pressure in dialysis patients—look before we leap – Authors' reply
by Perkovic, Vlado
The Lancet (British edition), 2009, Vol.373 (9679), p.1945-1946
16.
Renal effects of canagliflozin in type 2 diabetes mellitus
by Perkovic, Vlado
Current medical research and opinion, 2015-12-02, Vol.31 (12), p.2219-2231
17.
The Burden of Blood Pressure-Related Disease: A Neglected Priority for Global Health
by Perkovic, Vlado
Hypertension (Dallas, Tex. 1979), 2007-12, Vol.50 (6), p.991-997
18.
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
by Levin, Adeera, Dr
The Lancet (British edition), 2017-10-21, Vol.390 (10105), p.1888-1917
19.
Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data
by Sundström, Johan
The Lancet (British edition), 2014-08-16, Vol.384 (9943), p.591-598
20.
Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial
by Joshi, Rohina
Expert review of endocrinology & metabolism, 2009-03-01, Vol.4 (2), p.111-118
